Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check34 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 13, 2025. However, the deletion of the date March 25, 2025, does not indicate any significant change in core content or important information.SummaryDifference1.0%
- Check78 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check92 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check99 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.